Deals
A consortium comprised of the Russian Direct Investment Fund (RDIF), the European Bank for Reconstruction and Development (EBRD) and the CapMan Russia II fund has completed an investment in MAYKOR, a Russian IT outsourcing and service provider.
The three partners will invest up to USD100m in MAYKOR that will allow the group to grow its market share. The RDIF will invest USD50m, with the EBRD and the CapMan Russia II fund contributing the remaining part.
The new funds will support MAYKOR’s growth strategy to increase the scale of its operations and its service portfolio diversification inside Russia.
Chiesi Group, a European pharmaceutical company, has signed through its UK affiliate Chiesi Ltd a definitive agreement with Sunstone Capital to acquire Zymenex, a biopharmaceutical group focused on research and development of biologic therapeutics for the treatment of rare and life threatening genetic diseases.
Terms of the transaction have not been disclosed.
The acquisition of Zymenex includes Lamazym, a phase III recombinant enzyme indicated for use to treat patients suffering from alpha-Mannosidosis, as well as other early stage compounds.
Zymenex R&D capabilities will establish a research and development position for Chiesi in the recombinant biologics market for
Aquiline Capital Partners has made an investment, through affiliates, in Tourmalet Advisors, an alternative investment manager based in Fairfield, Connecticut.
Tourmalet, led by chief executive officer Michael Corasaniti, was founded in October 2009 and has a track record of managing, investing, structuring and trading distressed residential mortgage assets. The firm’s objective is to generate superior risk adjusted returns through the purchase, servicing and liquidation of distressed whole loans.
“We have known Mike Corasaniti and his team at Tourmalet for a number of years and have been impressed with their expertise and approach to investing in the residential mortgage
Qualcomm is to sell Omnitracs, its North and Latin American transportation and logistics business, to Vista Equity Partners, a US-based private equity firm.
Subject to the terms and conditions of the definitive agreement, Vista will purchase Omnitracs for USD800m in cash.
"In the late 1980s, Qualcomm pioneered the use of commercial vehicle telematics with the introduction of the first mobile information system for transportation and logistics. As one of Qualcomm’s earliest businesses, Omintracs has maintained a leadership position within the industry for 25 years. Today, the opportunity for fleet management and telematics is evolving rapidly, and we believe
Keating Capital, a pre-IPO investor and business development company, has made an additional USD1m convertible note investment in SilkRoad, an existing portfolio company.
Keating Capital’s investment is part of a USD16m growth financing round completed by SilkRoad.
Other participants in the financing include Foundation Capital, Intel Capital, Azure Capital Partners and Crosslink Ventures.
SilkRoad intends to use the new funding to fuel ongoing product innovation across SilkRoad’s Life Suite talent management software to support company growth.
Chicago-based SilkRoad is a provider of cloud-based human capital management (HCM) solutions to small- and medium-sized businesses (SMBs). SilkRoad’s Life
Private equity firm Thoma Bravo has completed its acquisition of Keynote Systems, a provider of internet and mobile cloud testing and monitoring, for USD20 per share or approximately USD395m.
With the transaction completed, Keynote’s stock will cease trading on the Nasdaq under the ticker symbol KEYN.
Keynote will remain headquartered in San Mateo, California. In addition, retiring chief executive Umang Gupta will transition the CEO role to software and technology industry veteran Jennifer Tejada.
“Jennifer brings a passion for innovation and unparalleled experience to hit the ground running with the tremendous platform that Umang and the Keynote team
TagMan, a tag management system, marketing data and marketing attribution provider, has received USD5m in new funding.
Existing investors Greycroft Partners and iNovia Capital led the financing, and Silicon Valley Bank also injected capital.
TagMan plans to use the awarded funds to ramp up growth of its 300-strong global partnership programme STREAM, which was launched in October 2012 and to support the growth of the company’s customer base globally. STREAM offers its certified partners streamlined tag implementations, reliable real-time, tag enabled data collection and clean, cross-channel marketing data from an independent source. The programme is open to best-in-class application
MicuRx Pharmaceuticals, a privately-held biopharmaceutical company developing next-generation antibiotics, has raised USD25m in series B financing.
Led by BVCF, a private equity and growth fund specialising in the life sciences industry, the round also includes existing investors Morningside Group and Devon Park Bioventures.
Proceeds from the series B financing will be used to fund the US development of MRX-I, a novel oral oxazolidinone antibiotic targeting infections due to multi-drug resistant Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). Weixin Xu and Davis Yang of BVCF will join the MicuRx board of directors.
"We invest in
EQT Infrastructure II has completed the refinancing of Synagro Technologies under a comprehensive plan of reorganisation approved by the court with the full support of the company’s creditors via the Chapter 11 process.
Synagro is an organic residuals management provider in the US.
Through working constructively with its creditors and backed by EQT Infrastructure II, Synagro’s balance sheet has been completely restructured, including an approximate USD200m reduction in outstanding debt. The new capital structure leaves Synagro with ample operational flexibility to execute on attractive growth opportunities.
"The new balance sheet and support from EQT’s Industrial Network will enable
Private equity firm Levine Leichtman Capital Partners has partnered with management to complete a growth capital investment in Edison, New Jersey-based SFERRA Fine Linens.
SFERRA, founded in 1891, designs and produces branded, Italian luxury linen products of the highest quality for luxury retailers and hundreds of specialty boutiques. The company’s product offering consists of a wide assortment of bedding products which are complemented by a variety of table linens, bath items and decorative accessories.
SFERRA is the first investment from Levine Leichtman Capital Partners V.
Lauren Leichtman, co-founder and chief executive of LLCP, says: "We are
Events
12 November, 2026 – 8:00 am
12 November, 2026 – 5:00 pm
